Quince Therapeutics annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
Quince Therapeutics Debt-to-Equity Ratio Growth & History (QNCX)
Quince Therapeutics's debt-to-equity ratio was 0.49 for fiscal 2024.
View full Quince Therapeutics company overviewQuince Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 0.49 | 0.33 | +202.61% |
| 2023 | 2023-12-31 | 0.16 | 0.16 | +4232.09% |
| 2022 | 2022-12-31 | 0.00 | −0.01 | −61.72% |
| 2021 | 2021-12-31 | 0.01 | 0.01 | +278.14% |
| 2020 | 2020-12-31 | 0.00 | 0.00 | — |
| 2019 | 2019-12-31 | 0.00 | — | — |
Quince Therapeutics quarterly debt-to-equity ratio
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q1.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | 0.03 | −0.82 | −96.94% |
| Q3 2025 | 2025-09-30 | 0.45 | 0.10 | +29.90% |
| Q2 2025 | 2025-06-30 | 1.49 | 1.18 | +386.67% |
| Q1 2025 | 2025-03-31 | 0.85 | 0.66 | +348.88% |
| Q4 2024 | 2024-12-31 | 0.49 | 0.33 | +202.61% |
| Q3 2024 | 2024-09-30 | 0.34 | 0.34 | +46761.52% |
| Q2 2024 | 2024-06-30 | 0.31 | 0.30 | +17997.12% |
| Q1 2024 | 2024-03-31 | 0.19 | 0.19 | +6232.51% |
| Q4 2023 | 2023-12-31 | 0.16 | 0.16 | +4232.09% |
| Q3 2023 | 2023-09-30 | 0.00 | −0.00 | −77.77% |
| Q2 2023 | 2023-06-30 | 0.00 | −0.00 | −58.07% |
| Q1 2023 | 2023-03-31 | 0.00 | −0.00 | −6.42% |
| Q4 2022 | 2022-12-31 | 0.00 | −0.01 | −61.72% |
| Q3 2022 | 2022-09-30 | 0.00 | −0.01 | −67.50% |
| Q2 2022 | 2022-06-30 | 0.00 | −0.01 | −61.06% |
| Q1 2022 | 2022-03-31 | 0.00 | 0.00 | +35.51% |
| Q4 2021 | 2021-12-31 | 0.01 | 0.01 | +278.14% |
| Q3 2021 | 2021-09-30 | 0.01 | 0.01 | +265.04% |
| Q2 2021 | 2021-06-30 | 0.01 | 0.01 | +734.79% |
| Q1 2021 | 2021-03-31 | 0.00 | 0.00 | +366.15% |
| Q4 2020 | 2020-12-31 | 0.00 | 0.00 | — |
| Q3 2020 | 2020-09-30 | 0.00 | 0.00 | — |
| Q2 2020 | 2020-06-30 | 0.00 | 0.00 | — |
| Q1 2020 | 2020-03-31 | 0.00 | — | — |
| Q4 2019 | 2019-12-31 | 0.00 | — | — |
| Q3 2019 | 2019-09-30 | 0.00 | — | — |
| Q2 2019 | 2019-06-30 | 0.00 | — | — |
Quince Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Quince Therapeutics's debt-to-equity ratio increased from 0.00 to 0.49, a change of 0.49. The latest reported quarter, Q1 2026, shows 0.03.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Quince Therapeutics source filings ↗